Dyadic International (DYAI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $1.96 million, up from $397,000 year-over-year, driven by licensing and milestone payments, especially from Proliant and Inzyme partnerships.

• Net loss narrowed to $203,000 in Q3 2024 from $1.61 million in Q3 2023, reflecting higher revenue and lower R&D expenses.

• Strategic partnerships and collaborations in alternative proteins, human and animal health, and biopharma are accelerating commercialization and expanding the product portfolio.

• Expanded product portfolio with new recombinant proteins for molecular biology and cell culture applications.

• Issued $6 million in senior secured convertible notes in March 2024, strengthening liquidity for commercialization.

Financial highlights

• Q3 2024 revenue: $1.96 million (Q3 2023: $397,000); 9M 2024 revenue: $2.68 million (9M 2023: $2.21 million).

• Net loss for Q3 2024 was $203,000 ($0.01/share), a significant improvement from $1.61 million ($0.06/share) in Q3 2023.

• R&D expenses decreased to $460,000 from $716,000 year-over-year, reflecting reduced internal research activity.

• G&A expenses were $1.3 million, up 1.2% year-over-year.

• Cash and investment-grade securities totaled $10 million as of September 30, 2024, up from $7.3 million at year-end 2023.

Outlook and guidance

• Total cash burn for 2024 is expected to decrease significantly to approximately $4.7 million.

• Management expects existing cash, investments, and proceeds from convertible notes to fund operations for at least the next 12 months.

• Anticipates final $500,000 payment from Proliant partnership and first recombinant albumin product launch in H1 2025.

• New research-grade products, including DNASE-1 and alpha-lactalbumin, are planned for launch in 2025.

• Preclinical studies for Mpox vaccine to begin in Q4 2024.